IMAB

I MAB (IMAB)

I MAB

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:IMAB

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/11/21	21:00	PR Newswire (US)	I-Mab to Participate at the Piper Sandler Healthcare Conference	NASDAQ:IMAB	I MAB
2024/11/14	21:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMAB	I MAB
2024/11/14	21:00	PR Newswire (US)	I-Mab Reports Third Quarter 2024 Results	NASDAQ:IMAB	I MAB
2024/11/06	21:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMAB	I MAB
2024/11/06	21:00	PR Newswire (US)	I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer	NASDAQ:IMAB	I MAB
2024/11/06	06:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMAB	I MAB
2024/10/31	20:00	PR Newswire (US)	I-Mab to Release Q3 2024 Financial Results on November 14, 2024	NASDAQ:IMAB	I MAB
2024/10/30	20:00	PR Newswire (US)	I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024	NASDAQ:IMAB	I MAB
2024/10/28	20:00	PR Newswire (US)	I-Mab to Participate at the Truist Securities BioPharma Symposium	NASDAQ:IMAB	I MAB
2024/10/24	20:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMAB	I MAB
2024/09/23	20:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMAB	I MAB
2024/09/17	05:01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMAB	I MAB
2024/09/17	05:01	PR Newswire (US)	I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024	NASDAQ:IMAB	I MAB
2024/09/10	20:00	PR Newswire (US)	I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer	NASDAQ:IMAB	I MAB
2024/08/31	04:23	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMAB	I MAB
2024/08/28	20:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMAB	I MAB
2024/08/28	20:00	PR Newswire (US)	I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates	NASDAQ:IMAB	I MAB
2024/08/26	20:00	PR Newswire (US)	I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference	NASDAQ:IMAB	I MAB
2024/08/14	20:00	PR Newswire (US)	I-Mab to Release 1H 2024 Financial Results on August 28, 2024	NASDAQ:IMAB	I MAB
2024/08/07	20:59	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMAB	I MAB
2024/08/07	20:00	PR Newswire (US)	I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)	NASDAQ:IMAB	I MAB
2024/07/26	19:20	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:IMAB	I MAB
2024/07/17	19:24	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:IMAB	I MAB
2024/07/15	20:45	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMAB	I MAB
2024/07/15	20:30	PR Newswire (US)	I-Mab Announces Leadership Transitions	NASDAQ:IMAB	I MAB
2024/06/06	20:14	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMAB	I MAB
2024/06/06	20:00	PR Newswire (US)	I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer	NASDAQ:IMAB	I MAB
2024/06/05	20:11	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMAB	I MAB
2024/06/05	20:00	PR Newswire (US)	I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	NASDAQ:IMAB	I MAB
2024/05/31	06:33	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:IMAB	I MAB